Researchers identified 5 distinct clusters for disease exacerbation that went beyond disease labels for both asthma and chronic obstructive pulmonary disease (COPD). When examining common factors for ...

Treatment with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) compared with FF/VI or UMEC/VI reduced exacerbation-related costs associated with chronic ...

Chronic obstructive pulmonary disease (COPD) is a long-term lung disease affecting at least 15 million American adults. It’s also the fourth leading cause of disease-attributed death. This makes ...

A recent study explored exacerbation history to determine what it revealed about prognosis. The findings suggested that exacerbation severity history was predictive of future exacerbation status.

Clinical guidelines recommend use of exacerbation history in choosing therapies to predict the risk for chronic obstructive pulmonary disease exacerbations, but an analysis of data from three ...

Adding mepolizumab to inhaled triple therapy significantly improved exacerbation outcomes compared with placebo in adults with chronic obstructive pulmonary disease (COPD), based on data from the ...

Please provide your email address to receive an email when new articles are posted on . Included former smokers experienced at least two COPD exacerbations in the year prior to screening. Those ...